Key Highlights
- Oscar Health (OSCR) shares climbed approximately 11% on Wednesday following CEO Mark Bertolini’s acquisition of 1 million shares at $11.92 each.
- The $11.92M deal occurred through a private placement arrangement, where Oscar issued fresh shares directly to the CEO rather than through public market channels.
- Bertolini’s total holdings now stand at 10.2M shares, accounting for 10.87% of Oscar Health’s total equity.
- The stock had gained roughly 7% the previous day after federal authorities announced a 2.5% increase in Medicare Advantage payment rates for 2027.
- Despite recording $443.2M in net losses during 2025, Oscar forecasts 60% revenue expansion in 2026, projecting $18.7B–$19B in total revenue.
Oscar Health (OSCR) is currently valued at $14.43, reflecting a $2.21 increase (+15.29%) since market opening.
Oscar Health CEO Mark Bertolini captured market attention this week by acquiring 1 million OSCR shares at $11.92 per unit — representing an $11.92M commitment to the health insurance company’s future trajectory. Share prices responded with an approximately 11% surge Wednesday morning.
Regulatory documents filed after Tuesday’s market close revealed the transaction. Bertolini, who formerly led Aetna as CEO, executed the purchase on Monday, April 6.
The structure differs from conventional stock acquisitions. SEC Form 4 documents identify this as a private placement transaction — Oscar created 1 million fresh shares specifically for its CEO at the $11.92 closing price, matching the valuation used that same day for tax withholding on performance units that had recently vested.
Oscar Health collected $11.92M in new funding through this arrangement, while Bertolini expanded his position to 10.87%, totaling 10,196,876 shares. Existing shareholders experienced negligible dilution effects.
Financial Performance Analysis
Oscar’s 2025 results reveal a business expanding rapidly while operating in the red. Annual revenue reached $11.7B, advancing from $9.18B during 2024. Member enrollment achieved an all-time high of 3.4 million. The company recorded $443.2M in net losses, accompanied by $396.4M in operating losses.
Looking toward 2026, management projects $18.7B–$19B in revenue — representing approximately 60% annual growth — while aiming for a medical-loss ratio between 82.4%–83.4%. Wall Street analysts forecast EPS of $0.77 for 2026, signaling a potential shift into profitable territory.
Reaching these ambitious benchmarks presents significant challenges. Bertolini’s substantial personal investment indicates his confidence in achieving them.
Considering industry context: UnitedHealth Group reported $113.2B in Q4 2025 revenue, marking 12.3% year-over-year expansion. Centene and Molina Healthcare demonstrated single-digit growth rates. Oscar’s expansion trajectory stands distinctly above competitors, though profitability remains elusive.
Understanding the Transaction Structure
The mechanics of this acquisition deserve examination. Traditional open-market purchases — where executives buy shares at prevailing ask prices, accepting market spreads and potential immediate losses — generally convey stronger conviction signals. Such transactions demonstrate: “I believe current pricing represents value.”
Private placements operate differently. Bertolini didn’t submit a standard market order. He obtained shares at a predetermined fair market valuation, within a structured transaction connected to equity vesting. Oscar received capital; Bertolini received ownership.
Bertolini had the option to liquidate vested shares for tax obligations and collect cash proceeds. Instead, he elected to expand his holdings. Based on current market prices, his Oscar stake carries approximately $125M in value.
OSCR shares had already advanced roughly 7% on Tuesday following federal confirmation of a 2.5% Medicare Advantage payment rate increase for 2027 — exceeding the initial proposal to maintain flat reimbursement levels.
Oscar plans to release Q1 2025 earnings on May 6 during pre-market hours.
